New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia

被引:3
作者
Cluzeau, Thomas [1 ]
De Matteis, Muriel [2 ]
Mounier, Nicolas [1 ]
Mannone, Lionel [1 ]
Gratecos, Nicole [1 ]
Ticchioni, Michel [2 ]
Thyss, Antoine [4 ]
Raynaud, Sophie [3 ]
Cassuto, Jill-Patrice [1 ]
Sirvent, Anne [1 ]
机构
[1] CHU Nice, Dept Hematol, Nice, France
[2] CHU Nice, Immunol Lab, Nice, France
[3] CHU Nice, Hematol Lab, Nice, France
[4] Ctr Antoine Lacassagne, Dept Oncol, F-06054 Nice, France
关键词
BONE-MARROW-TRANSPLANTATION; MYELODYSPLASTIC SYNDROME; DISEASE; CHIMERISM; GRAFT;
D O I
10.1002/ajh.22029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A new sequential regimen for allogeneic stem-cell transplantation, comprising cytoreductive chemotherapy immediately followed by reduced-intensity conditioning (RIC), was evaluated in 17 intensively treated patients with refractory or early relapsed acute myeloid leukemia (AML). Cytoreductive chemotherapy comprised thiotepa (3 x 200 mg/m(2)), etoposide (3 x 200 mg/m(2)) and six mercapto-purine (75 mg/m(2) for 14 days) followed 2 days later, by RIC consisting of busilvex, Fludarabine and antithymocyte globulin. For six patients, the donor was a sibling and for 11, unrelated. The results showed that the procedure was safe. There were seven transplant-related deaths, mainly due to acute graft-versus-host disease and/or severe infection. Complete remission was observed in 13 patients at post-transplant Day 30. With a median follow-up of 14 months, overall survival and relapse-free survival were 29.4 and 17.7%, respectively. These results indicate a degree of antileukemia activity, which could probably be improved.
引用
收藏
页码:619 / 621
页数:3
相关论文
共 15 条
[1]   Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease [J].
Brunstein, Claudio G. ;
Barker, Juliet N. ;
Weisdorf, Daniel J. ;
DeFor, Todd E. ;
Miller, Jeffrey S. ;
Blazar, Bruce R. ;
McGlave, Philip B. ;
Wagner, John E. .
BLOOD, 2007, 110 (08) :3064-3070
[2]  
Buchholz SKJ, 2009, EBMT C
[3]   Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].
Cassileth, PA ;
Harrington, DP ;
Appelbaum, FR ;
Lazarus, HM ;
Rowe, JM ;
Paietta, E ;
Willman, C ;
Hurd, DD ;
Bennett, JM ;
Blume, KG ;
Head, DR ;
Wiernik, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656
[4]   Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome [J].
de Lima, M. ;
Champlin, R. E. ;
Thall, P. F. ;
Wang, X. ;
Martin, T. G., III ;
Cook, J. D. ;
McCormick, G. ;
Qazilbash, M. ;
Kebriaei, P. ;
Couriel, D. ;
Shpall, E. J. ;
Khouri, I. ;
Anderlini, P. ;
Hosing, C. ;
Chan, K. W. ;
Andersson, B. S. ;
Patah, P. A. ;
Caldera, Z. ;
Jabbour, E. ;
Giralt, S. .
LEUKEMIA, 2008, 22 (02) :258-264
[5]   An Old AML Drug Revisited [J].
Dombret, Herve ;
Gardin, Claude .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1301-1303
[6]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[7]  
HOROWITZ MM, 1990, BLOOD, V75, P555
[8]   High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia [J].
Lowenberg, Bob ;
Ossenkoppele, Gert J. ;
van Putten, Wim ;
Schouten, Harry C. ;
Graux, Carlos ;
Ferrant, Augustin ;
Sonneveld, Pieter ;
Maertens, Johan ;
Jongen-Lavrencic, Mojca ;
von Lilienfeld-Toal, Marie ;
Biemond, Bart J. ;
Vellenga, Edo ;
Kooy, Marinus van Marwijk ;
Verdonck, Leo F. ;
Beck, Joachim ;
Doehner, Hartmut ;
Gratwohl, Alois ;
Pabst, Thomas ;
Verhoef, Gregor .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1235-1248
[9]   SUCCESSFUL ALLOGENIC BONE MARROW TRANSPLANTATION IN MAN - CHIMERISM INDUCED SPECIFIC TOLERANCE AND POSSIBLE ANTI-LEUKEMIC EFFECTS [J].
MATHE, G ;
AMIEL, JL ;
SCHWARZE.L ;
CATTAN, A ;
SCHNEIDE.M ;
DEVRIES, MJ ;
TUBIANA, M ;
LALANNE, C ;
BINET, JL ;
PAPIERNI.M ;
SEMAN, G ;
MATSUKUR.M ;
MERY, AM ;
SCHWARZM.V ;
FLAISLER, A .
BLOOD-THE JOURNAL OF HEMATOLOGY, 1965, 25 (02) :179-&
[10]  
PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825